These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19384912)

  • 1. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.
    Lamb CA; Mohiuddin MK; Gicquel J; Neely D; Bergin FG; Hanson JM; Mansfield JC
    Br J Surg; 2009 Jun; 96(6):663-74. PubMed ID: 19384912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
    Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
    Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
    Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin in the assessment of Crohn's disease activity.
    Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
    QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.
    Joshi S; Lewis SJ; Creanor S; Ayling RM
    Ann Clin Biochem; 2010 May; 47(Pt 3):259-63. PubMed ID: 19740914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease.
    Joishy M; Davies I; Ahmed M; Wassel J; Davies K; Sayers A; Jenkins H
    J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):48-54. PubMed ID: 19172123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.
    Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
    Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
    Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
    Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Calprotectin and Modified Rutgeerts Score.
    Lopes S; Andrade P; Afonso J; Rodrigues-Pinto E; Dias CC; Macedo G; Magro F
    Inflamm Bowel Dis; 2016 Sep; 22(9):2173-81. PubMed ID: 27482974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study.
    Sidhu R; Sanders DS; Wilson P; Foye L; Morley S; McAlindon ME
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):257-60. PubMed ID: 20922188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.